Expanding the toolbox for drug design: New enzymes for tailoring molecules

Simon Schröder has worked out how enzymes can be used to more easily form the desired bond between two nitrogen atoms.

GSK seeks to extend RSV vaccine use in adults aged 50-59 years

Share this article GSK’s RSV vaccine could soon be available for adults aged 50-59 at risk of RSV disease. Credit: GSK plc. The European Medicines

January 30, 2024

Immunotherapy After Definitive Therapy Flops in Head and Neck Cancer

SAN DIEGO — Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) who received atezolizumab (Tecentriq) after undergoing multimodal definitive therapy

April 11, 2024

Positive Results for Odronextamab in Relapsed/Refractory DLBCL

In a pivotal phase II study, the investigational bispecific antibody odronextamab demonstrated clinically meaningful efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma

December 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.